Abstract 16P
Background
Peritoneal metastasis is a relatively common manifestation of poor prognosis and resistance to immune checkpoint blockades in patients with gastric cancer (GC). In the present study, we aimed to investigate the exhaustion status of CD8+ T cells and immunosuppressive soluble factors in malignant ascites from patients with GC and peritoneal metastasis.
Methods
We obtained pathologically confirmed malignant ascites samples along with peripheral blood from 27 patients with GC peritoneal metastasis and examined the exhaustion status of CD8+ T cells using multicolor flow cytometry. A multiplex enzyme-linked immunosorbent assay for immunosuppressive soluble factors, including matrix metalloproteinase-2 (MMP-2), MMP-7, transforming growth factor beta (TGF-β), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), E-cadherin, and angiopoietin-2, was performed on 45 cell-free fluid samples (15 paired malignant ascites and plasma of patients with GC and 15 benign ascites of liver cirrhosis patients).
Results
CD8+ T cells in the malignant ascites of GC showed significantly increased expression of PD-1, TIGIT, and TIM-3 compared with peripheral blood CD8+ T cells. CD8+ T-cells in malignant ascites had more terminally differentiated phenotypes (T-betlowEomeshigh) and tumor antigen reactivity (CD39+ CD103+) than peripheral blood CD8+ T cells. The expression levels of immunosuppressive soluble factors, including MMP-2, MMP-7, TGF-β, HGF, VEGF, E-cadherin, and angiopoietin-2, were significantly higher in the malignant ascites than in the plasma of patients with GC or in the benign ascites of liver cirrhosis patients.
Conclusions
We found that CD8+ T cells in the malignant ascites of GC are terminally exhausted and tumor antigen-reactive T cells. Furthermore, immunosuppressive soluble factors were significantly increased in cell-free fluid of malignant ascites of GC. Thus, the present findings suggest that the co-blockade of immune checkpoints and immunosuppressive soluble factors may be a feasible therapeutic option for patients GC with peritoneal metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09